ADC Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ADC Therapeutics wird ein Gewinn- und Umsatzwachstum von 21.3% bzw. 31% pro Jahr prognostiziert, während der Gewinn pro Aktie um 31.8% pro Jahr wachsen soll.

Wichtige Informationen

21.3%

Wachstumsrate der Gewinne

31.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	31.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10

Recent updates

Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%

Nov 16

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Jul 18

Limiting Concerns On ADC Therapeutics' Prospects

Jun 06

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

May 30

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Dec 29

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

Dec 14

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

May 11

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Apr 18

ADC Therapeutics stock slips after pricing stock offering by seller

Feb 02

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jan 16

Jose Carmona joins ADC Therapeutics as CFO

Dec 19

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

Nov 08

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

Sep 16

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Sep 09

Gewinn- und Umsatzwachstumsprognosen

NYSE:ADCT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	112	-161	-42	-149	6
12/31/2025	83	-172	-92	-157	7
12/31/2024	73	-165	-86	-128	6
9/30/2024	71	-212	-135	-134	N/A
6/30/2024	67	-215	-147	-145	N/A
3/31/2024	69	-227	-150	-147	N/A
12/31/2023	70	-240	-122	-119	N/A
9/30/2023	123	-181	-142	-141	N/A
6/30/2023	184	-184	-103	-102	N/A
3/31/2023	182	-200	-120	-120	N/A
12/31/2022	210	-157	-139	-138	N/A
9/30/2022	157	-166	-149	-146	N/A
6/30/2022	94	-187	-212	-207	N/A
3/31/2022	80	-195	-219	-212	N/A
12/31/2021	34	-230	-240	-233	N/A
9/30/2021	17	-252	-230	-223	N/A
6/30/2021	4	-200	-215	-209	N/A
3/31/2021	N/A	-254	-195	-192	N/A
12/31/2020	N/A	-246	-172	-169	N/A
9/30/2020	N/A	-226	-153	-151	N/A
6/30/2020	N/A	-237	-140	-139	N/A
3/31/2020	1	-135	-128	-126	N/A
12/31/2019	2	-116	-124	-122	N/A
9/30/2019	3	-112	-121	-118	N/A
6/30/2019	3	-111	-119	-116	N/A
3/31/2019	2	-117	-122	-118	N/A
12/31/2018	1	-123	-124	-121	N/A
12/31/2017	2	-90	N/A	-75	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ADCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ADCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ADCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ADCTDie Einnahmen des Unternehmens (31% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: ADCTDie Einnahmen des Unternehmens (31% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ADCT in 3 Jahren voraussichtlich hoch sein wird

ADC Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 12% to US$8.60

Consensus EPS estimates upgraded to US$1.84 loss, revenue downgraded

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

Consensus EPS estimates fall by 13%, revenue upgraded

Price target increased by 19% to US$10.50

Price target increased by 12% to US$8.80

Recent updates

Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%

Price target decreased by 12% to US$8.60

Third quarter 2024 earnings: EPS misses analyst expectations

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ADC Therapeutics SA has filed a Follow-on Equity Offering in the amount of $100 million.

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Limiting Concerns On ADC Therapeutics' Prospects

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

Consensus EPS estimates upgraded to US$1.84 loss, revenue downgraded

CEO & Director recently sold US$133k worth of stock

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $105 million.

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

ADC Therapeutics SA has filed a Follow-on Equity Offering.

ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

ADC Therapeutics: Navigating A Swirling Drain

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Price target increased by 19% to US$10.50

Price target increased by 12% to US$8.80

New major risk - Share price stability

Consensus revenue estimates fall by 11%

ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

ADC Therapeutics: Slowly Moving Toward Solvency

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 20%, EPS upgraded

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ADC Therapeutics SA to Report Q2, 2023 Results on Aug 08, 2023

China National Medical Products Administration Accepts Biologics License Application and Grants Priority Review for ZYNLONTA for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA Announces Voluntary Pause in the Enrollment of New Patients in the Phase 2 LOTIS-9 Clinical Trial Evaluating ZYNLONTA

Now 31% undervalued after recent price drop

Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

High number of new directors

Price target decreased by 18% to US$9.33

ADC Therapeutics SA Announces Evolution of Board of Directors

ADC Therapeutics SA Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA(R) in Relapsed/Refractory DLBCL

ADC Therapeutics: Maybe A 2024 Story

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target increased by 9.4% to US$12.40

Consensus revenue estimates decrease by 29%, EPS upgraded

ADC Therapeutics SA Announces Updated Results from LOTIS-2 Trial to Be Presented at the European Hematology Association 2023 Hybrid Congress

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

ADC Therapeutics SA, Annual General Meeting, Jun 14, 2023

Price target increased by 8.5% to US$13.20

Price target increased by 7.4% to US$13.20

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Consensus revenue estimates fall by 16%

Price target decreased by 15% to US$11.14

Price target decreased by 8.5% to US$12.29

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $60 million.

ADC Therapeutics stock slips after pricing stock offering by seller

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

ADC Therapeutics SA Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

ADC Therapeutics Sa Appoints Jose Carmona as Chief Financial Officer

Jose Carmona joins ADC Therapeutics as CFO

Price target decreased to US$14.17